High tumour mutation burden (TMB) has been shown to be a biomarker for immunotherapeutic response for treatments that inhibit programmed cell death 1/programmed death‐ligand 1 (PD‐1/PD‐L1) ligation in multiple tumours, thereby improving the survival of cancer patients.21 The gene discussed is PDCD1; the disease is cancer.